J.P. Morgan analyst James Gordon maintained a Sell rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £14.40.

GlaxoSmithKline's consumer health business will be named Haleon following its planned spinoff and listing on the London Stock Exchange later this year, according to the drugmaker. The name of the ...

GlaxoSmithKline would consider buying Pfizer’s consumer health business – but only if the price is right, according to the company's chief executive. Emma Walmsley has also been busy shaking ...

GSK Consumer’s (GSK’s) Q2FY19 revenue, Ebitda and PAT growth of 14%, 35% and 43% y-o-y, respectively, surpassed estimates. This was the fourth consecutive quarter of strong volume spurt ...

UBS analyst Jo Walton maintained a Hold rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of p1,580.00. The ...

GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the ...

We recently published a list of 12 Undervalued Defensive Stocks for 2025. In this article, we are going to take a look at ...

ICICI Direct recommended hold rating on GSK Consumer with a target price of ... of Boost and Horlicks will see lower volume growth in health food drinks and earnings growth over three years ...